158 filings
ARS
2023 FY
KROS
Keros Therapeutics Inc
17 Apr 24
Annual report to shareholders
4:08pm
DEFA14A
KROS
Keros Therapeutics Inc
17 Apr 24
Additional proxy soliciting materials
4:05pm
DEF 14A
KROS
Keros Therapeutics Inc
Definitive proxy
17 Apr 24
4:02pm
8-K
KROS
Keros Therapeutics Inc
14 Mar 24
Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes
8:01am
8-K
KROS
Keros Therapeutics Inc
6 Mar 24
March 2024 Corporate Presentation
8:01am
8-K
20ky 83gghrzn8z
5 Mar 24
Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma Conference
8:02am
8-K
toeronvm pax
5 Mar 24
Departure of Directors or Certain Officers
8:01am
S-8
ca40hmet0 0oyahedk
28 Feb 24
Registration of securities for employees
5:41pm
8-K
fcgaq
28 Feb 24
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
4:02pm
8-K
swhauuxr
9 Jan 24
Keros Therapeutics Announces Closing of Upsized Public Offering of Common Stock
8:01am
8-K
0z1t1hy qmekpjnd8g
4 Jan 24
Other Events
4:04pm
424B5
tza5yuea rrjv1p
4 Jan 24
Prospectus supplement for primary offering
4:02pm
424B5
1zrdl0f y2le
3 Jan 24
Prospectus supplement for primary offering
4:04pm
8-K
0tuj46b 6ne
3 Jan 24
January 2024 Corporate Presentation
8:04am
8-K
fwl ejxh16e5
11 Dec 23
Keros Therapeutics Presents Clinical Data from its KER-050 Program at the 65th American Society of Hematology Annual Meeting and Exposition
6:02am
8-K
onv2hs ri19pfzz3178a
7 Nov 23
Keros Therapeutics to Present at Upcoming Healthcare Conferences
8:01am
8-K
5mh041 k2qb
6 Nov 23
November 2023 Corporate Presentation
8:11am
8-K
f3sk81hu
6 Nov 23
Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2023 Financial Results
8:01am
8-K
b4p4csp90lukf
4 Oct 23
Keros Therapeutics Presents Preclinical Data from its KER-065 Program at the 28th International Annual Congress of the World Muscle Society
8:01am